MedinCell S.A. is a clinical-stage and commercial-stage pharmaceutical company focused on the development of long-acting injectable treatments. The company's core innovation is its proprietary BEPO technology, which uses a combination of copolymers and a biocompatible solvent to create a subcutaneous or intramuscular depot that steadily releases active pharmaceutical ingredients. MedinCell's business model relies on partnering with established pharmaceutical companies, such as Teva Pharmaceuticals, to co-develop and commercialize its formulations. Its most notable product is UZEDY, a long-acting risperidone treatment for schizophrenia approved by the U.S. FDA. The company's pipeline spans multiple therapeutic areas, including psychiatry, pain management, and contraception. By reformulating proven drugs, MedinCell aims to improve patient adherence, enhance efficacy, and reduce side effects.
